Success Story: Dual NIW & EB1A Success Despite RFE! We Helped A Postdoctoral Associate Get Approval Swiftly with Premium Processing

“Amazing news, thank you for your beautiful work putting the application together and addressing the RFE. It has been great working with you.”

Case Summary:      

We are pleased to announce the approval of both an EB-2 National Interest Waiver (NIW) petition and an EB-1A (Individuals with Extraordinary Ability) petition for an outstanding researcher in biotechnology. The NIW was approved in January 2025, and the EB-1A was approved in August 2025, following a successful response to a request for evidence (RFE).

Research Focus and Contributions:
With a Ph.D. in cancer biology, the client has established himself as a leading expert in molecular and cellular biology, genome organization and regulation, cancer cell biology, and cellular signaling. Within biotechnology, he is particularly recognized for advancing the development of CRISPRoff, a novel epigenome editor that expands the frontiers of genome engineering. His pioneering research is shaping new strategies for controlling gene expression with implications for cancer treatment, regenerative medicine, and therapeutic development.

Publications and Citations:
The client has authored 18 peer-reviewed journal articles (5 of them first- or co-first-authored) and 9 abstracts (including 1 first-authored). His research has been cited 1,552 times according to Google Scholar, reflecting the significant impact of his contributions and the reliance of independent researchers on his findings across multiple disciplines in biology and medicine.

Service to the Field:
In addition to his publication record, the client has conducted at least 10 peer reviews for respected journals. His service as a reviewer underscores the recognition of his expertise and his trusted role in guiding the work of fellow scientists.

Funding and Recognition:
 The importance of his research is further demonstrated by major funding support from organizations such as the National Institutes of Health (NIH), the National Cancer Institute (NCI), and Cancer Research UK. His achievements have also earned him recognition outside academia, including selection for the prestigious Forbes 30 Under 30 list in the Science category.

Expert Support:
To strengthen the petitions, four recommendation letters were submitted from internationally recognized experts in biotechnology and cancer research. These recommenders emphasized the originality of his methods, the broad applicability of his findings, and the transformative role of his work in advancing genome editing technologies.

“His strong research record also testifies to his exceptional capacity to address critical medical and healthcare challenges, highlighting the value of his ongoing research in the United States.”

NIW & EB1A Approvals and Outlook:
The approvals of both the NIW and EB-1A petitions confirm that the client is not only making research contributions of substantial merit and national importance but has also risen to the very top of his field. With a strong record of publications, high citation impact, peer-review service, prestigious funding, and global recognition, he is exceptionally well-positioned to continue advancing biotechnology and cancer research in the United States.

At NAILG, we congratulate our client on these significant achievements and look forward to his continued impact in the fields of biotechnology and molecular biology.